Compare ACM Research Inc (ACMR) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

ACMR trades at $81.26, up 2.33% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.61 versus $0.42 expected, revenue growth of 36% year-over-year to $292.9 million, and raised 2026 guidance. Net income margin improved to 14.48% in 2026 from 10.43% in 2025, supported by robust orders and product expansion.

Outlook remains positive with an 80% analyst buy rating and consensus price target of $127.50, implying significant upside. Risks include high P/E of 37.7, negative operating cash flow, and semiconductor cycle volatility. Growth catalysts are new wet processing platforms and overseas expansion, but execution on guidance is critical.

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.